The firm will use the funds to continue its commercialization plans for the Unyvero diagnostic test cartridges and instruments.
Funds raised through the offering will be used to buy back shares of common stock from shareholders in privately negotiated transactions.
The company said it will use the proceeds from the offering for general corporate and working capital purposes.
The firm said it intends to use net proceeds from the issuance of the notes for general corporate purposes.
The company said it will use the funds to develop antimicrobial therapeutics based on CRISPR-Cas3 technology.
The Salt Lake City-based company said it would use the $18.4 million in expected gross aggregate proceeds for product pipeline development and customer growth.
The firm privately negotiated the exchange with current holders of convertible notes due 2017.
Quidel will use the net proceeds from the offering for working capital and other general corporate purposes.
PositiveID will issue $4 million in senior secured convertible promissory notes to institutional investor Dominion Capital, the firm announced today.
NEW YORK (GenomeWeb News) – Qiagen said after the close of the market on Wednesday that it successfully completed the previously announced repurchase of convertible notes due in 2026 and the issuance
Researchers are refining a tool to predict a woman's risk of developing breast cancer, according to the Guardian.
According to Stat News, the partial government shutdown in the US could soon affect the ability of the Food and Drug Administration to review new drugs.
CNN reports that people's genes tend to have a greater influence on their risk of developing disease than their environment, but it varies by phenotype.
In PNAS this week: gypsy moth genome sequenced, phylogenomic analysis of Polyneopterans, and more.